196 related articles for article (PubMed ID: 2560421)
1. Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains.
Jones RN; Pfaller MA; Fuchs PC; Aldridge K; Allen SD; Gerlach EH
Diagn Microbiol Infect Dis; 1989; 12(6):489-94. PubMed ID: 2560421
[TBL] [Abstract][Full Text] [Related]
2. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase.
Knapp CC; Sierra-Madero J; Washington JA
Diagn Microbiol Infect Dis; 1989; 12(6):511-5. PubMed ID: 2560423
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).
Eliopoulos GM; Klimm K; Ferraro MJ; Jacoby GA; Moellering RC
Diagn Microbiol Infect Dis; 1989; 12(6):481-8. PubMed ID: 2560420
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of YTR 830.
Jacobs MR; Aronoff SC; Appelbaum PC; Yamabe S
J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
[TBL] [Abstract][Full Text] [Related]
6. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
Jones RN; Barry AL
Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422
[TBL] [Abstract][Full Text] [Related]
7. Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. A reevaluation after five years.
Marshall SA; Aldridge KE; Allen SD; Fuchs PC; Gerlach EH; Jones RN
Diagn Microbiol Infect Dis; 1995 Mar; 21(3):153-68. PubMed ID: 7648836
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria.
Venezia RA; Yocum DM; Robbiano EM; Echols RM
Antimicrob Agents Chemother; 1990 Sep; 34(9):1858-61. PubMed ID: 2178340
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of the in vitro activity of piperacillin/tazobactam.
Daley D; Mulgrave L; Munro R; Neville S; Smith H; Dimech W
Pathology; 1996 May; 28(2):167-72. PubMed ID: 8743825
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
Klepser ME; Marangos MN; Zhu Z; Nicolau DP; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 1997 Feb; 41(2):435-9. PubMed ID: 9021203
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
Fass RJ; Prior RB
Antimicrob Agents Chemother; 1989 Aug; 33(8):1268-74. PubMed ID: 2552904
[TBL] [Abstract][Full Text] [Related]
12. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Nomura S; Hanaki H; Nagayama A
J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
[TBL] [Abstract][Full Text] [Related]
13. Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Pagani L; Migliavacca R; Luzzaro F; Giacobone E; Perilli M; Micheletti P; Amicosante G
Chemotherapy; 1998; 44(6):377-84. PubMed ID: 9755296
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of 114 isolates of the Bacteroides fragilis group to imipenem and eight other antimicrobial agents.
Downes J; Andrew JH
Pathology; 1988 Jul; 20(3):260-3. PubMed ID: 3205597
[TBL] [Abstract][Full Text] [Related]
15. Piperacillin/tazobactam and ticarcillin/clavulanic acid against resistant Enterobacteriaceae.
Kempers J; MacLaren DM
J Antimicrob Chemother; 1990 Oct; 26(4):598-9. PubMed ID: 2174855
[No Abstract] [Full Text] [Related]
16. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
17. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
[TBL] [Abstract][Full Text] [Related]
18. Turbidimetric and microscopic analysis of Bacteroides fragilis exposed to tazobactam and piperacillin alone and in combination.
Yourassowsky E; Van der Linden MP; Lismont MJ; Crokaert F
Chemotherapy; 1990; 36(3):215-21. PubMed ID: 2159865
[TBL] [Abstract][Full Text] [Related]
19. [Bactericidal activity of combinations of ticarcillin-clavulanic acid or other beta-lactams (amoxicillin, piperacillin-tazobactam, ticarcillin) with gentamicin against Enterococcus faecalis and E. faecium].
Leclercq R; Duval J
Pathol Biol (Paris); 1995 Apr; 43(4):245-52. PubMed ID: 7567109
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial spectrum of cefpirome combined with tazobactam against the Bacteroides fragilis group.
Jones RN; Croco JL; Barrett MS; Novick WJ; Erwin ME
Diagn Microbiol Infect Dis; 1990; 13(5):371-3. PubMed ID: 2178078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]